Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a leading medical products company specializing in the science, development, and commercialization of technologies for peripheral nerve repair and regeneration. The company's core mission is to restore peripheral nerve function and improve the quality of life for patients suffering from traumatic injuries or surgical procedures that impact nerve function and sensation.
Axogen's innovative product portfolio includes:
- Avance® Nerve Graft: The first and only commercially available allograft for bridging nerve discontinuities.
- Axoguard® Nerve Connector: A coaptation aid designed for the close approximation of severed nerves.
- Axoguard® Nerve Protector: A product that shields nerves during the healing process.
- Axoguard® Nerve Cap: A surgical implant to isolate and protect a peripheral nerve end, minimizing painful neuroma development.
- Axoguard HA+ Nerve Protector: A next-gen nerve protection device designed to provide both short- and long-term protection for peripheral nerve injuries.
- Avive® Soft Tissue Membrane: A biologically active product aiding in nerve healing.
- Axotouch® Two-Point Discriminator: An assessment tool for measuring the innervation density of skin surface areas.
Axogen's products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. The company continues to expand its global presence and partnerships, ensuring that healthcare providers and surgeons have access to clinically and economically effective nerve repair solutions.
Recent achievements include the launch of the Axoguard HA+ Nerve Protector, which provides enhanced nerve gliding and protection for a wide range of peripheral nerve injuries. The company reported strong performance in Q4 2023, with an expected annual revenue growth of 11% to 14% and anticipated gross margins between 76% and 79%.
For more information, visit www.axogeninc.com.
Axogen, Inc. (NASDAQ: AXGN) reported first-quarter 2022 financial results with net revenue of $31.0 million, unchanged from the same period in 2021. Adjusted net loss widened to $8.5 million or $0.20 per share, compared to $3.1 million or $0.08 per share last year. Gross margin decreased to 82.1% from 83.3%. The company expects 2022 revenue between $135.0 million and $142.0 million, reflecting anticipated growth. Key developments include the successful completion of the RECON Phase 3 study for Avance Nerve Graft, providing significant clinical evidence for its use.
Axogen announced that its RECON Clinical Study successfully met its primary endpoint by demonstrating the superiority of Avance Nerve Graft in returning sensory function in digital nerve injuries. The study showed that Avance outperformed conduits, especially in gaps exceeding 12 mm, achieving significant recovery times up to 3 months faster. With results supporting a Biologics License Application (BLA) submission in late 2023, this milestone bolsters Avance's market adoption potential.
Axogen, Inc. (NASDAQ: AXGN) announced it will release its first quarter 2022 financial results on May 4, 2022, after market close. The management team will conduct a conference call and webcast at 4:30 p.m. ET to discuss the results. Interested parties can join by calling (877) 407-0993 for the toll-free option or (201) 689-8795 directly. A live webcast will also be available on the company's website. Axogen is focused on innovative surgical solutions for peripheral nerve injuries, offering a range of products aimed at restoring nerve function.
Axogen, Inc. (NASDAQ: AXGN) reported Q4 and full-year 2021 financial results, showing a 3% decline in Q4 revenue at $31.5 million compared to Q4 2020. Full-year revenue rose 13% to $127.4 million.
The adjusted net loss for Q4 stood at $3.3 million, unchanged from the previous year, while the gross margin was 82.8%. The company anticipates 2022 revenue between $135 million and $142 million, projecting growth of 10% to 15% over 2021.
Axogen, Inc. (NASDAQ: AXGN) will participate in two upcoming investor conferences in February 2022. CEO Karen Zaderej will engage in a fireside chat at the BTIG Virtual MedTech Conference on February 15 at 1:25 p.m. ET and at the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 1:40 p.m. ET. Both discussions will be accessible via Axogen's Investors page, with a replay available post-event for 90 days. Axogen specializes in innovative solutions for peripheral nerve injuries, focusing on restoring nerve function and improving patient quality of life.
Axogen, Inc. (AXGN) will report its fourth quarter and full-year 2021 financial results on February 22, 2022, post-market. An investment-community conference call will be held at 4:30 p.m. ET, accessible via phone or live webcast through their website. Axogen specializes in surgical solutions for peripheral nerve injuries, offering products like Avance Nerve Graft and Axoguard Nerve Connector. Their portfolio aims to restore nerve function and quality of life for patients worldwide.
Axogen (NASDAQ: AXGN) reported expected fourth quarter revenue of approximately $31.5 million, down 3% from $32.5 million in Q4 2020. For the full year 2021, revenue is projected to be around $127.3 million, marking a 13% increase from $112.3 million in 2020. The decline in Q4 revenue is attributed to surgical volume fluctuations and COVID-19 impacts. The company expanded its sales force and core accounts, with 294 Core Accounts, a 9% increase year-over-year. Axogen anticipates releasing RECON study results in Q2 2022.
Axogen (AXGN) will feature its nerve repair platform at the combined 2022 meetings of the American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery from January 11-18 in Carlsbad, CA. An educational symposium on January 13 will discuss evidence-based nerve repair strategies. Key presentations include studies on nerve grafts and reconstruction techniques. CEO Karen Zaderej emphasized the growing interest in peripheral nerve repair and Axogen's commitment to patient outcomes through innovative solutions.
Axogen, Inc. (NASDAQ: AXGN) announces that patient Christopher Brown will feature in the 2022 Donate Life Rose Parade Float, honoring organ donor Paul Flanders. The event, aimed at raising awareness for organ and tissue donation, will take place on New Year’s Day in Pasadena, CA. Brown's recovery from chronic pain due to nerve damage after an amputation was made possible through nerve repair surgery using donated tissue. Axogen's CEO, Karen Zaderej, emphasized the importance of donation and the company's commitment to improving quality of life for nerve injury patients.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
What is Axogen, Inc. focused on?
What are some key products offered by Axogen?
In which markets are Axogen's products available?
What recent product did Axogen launch?
What is the Avance® Nerve Graft?
How did Axogen perform financially in Q4 2023?
What does the Axoguard® Nerve Cap do?
What is the function of the Axotouch® Two-Point Discriminator?
Who is the current CEO of Axogen?
Where can I find more information about Axogen?
